Ceftaroline fosamil, a prodrug of the active metabolite, ceftaroline, is a novel broad-spectrum cephalosporin approved recently by Food and Drug Administration (FDA) for treating acute bacterial skin and soft tissue infections comprising those caused by methicillin-resistant Staphylococcus aureus (MRSA) in adults and community-acquired bacterial pneumonia (CABP). The current article focuses a quick comprehensive glance about the drug molecule.
Cephalosporin a class of antimicrobial agents is well known because of their broad spectrum activity, proven efficacy and favourable safety profile, thereby making it the most commonly prescribed class of antimicrobials. Ceftaroline fosamil, a cephalosporin with in vitro bactericidal activity against pathogens has been associated with licensed indications including resistant organisms, such as methicillin-resistant Staphylococcus aureus (MRSA),…
